Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM13PQW)

• Drug Name: Rilmenidine Drug Info
• Synonyms: Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]

• Cross-matching ID:
  PubChem CID: 68712
  ChEBI ID: CHEBI:8862
  CAS Number: CAS 54187-04-1
  TTD Drug ID: DM13PQW

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Modulator	[2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	5.013	2.379	5.594	2.07

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Hypertension
• ICD Disease Classification: BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	1.76E-01	-0.06	-0.28

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.